1. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE (2001) Dose–response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21: 3425–3432
2. Arun B, Zhang H, Mirza NQ (2001) Growth inhibition of breast cancer cells by celecoxib. Breast Cancer Res Treat 69: 234 (Abstract)
3. Banu A, Goss P (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Sem Oncol 31: 22–29
4. Bennett A (1986) The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 25: 539–542
5. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423–429